Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on December 1, 2003

Circulation. 2003
Published online before print December 1, 2003, doi: 10.1161/01.CIR.0000105900.21445.3D
A more recent version of this article appeared on December 9, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/23/2864    most recent
01.CIR.0000105900.21445.3Dv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Golino, P.
Right arrow Articles by Chiariello, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Golino, P.
Right arrow Articles by Chiariello, M.
Related Collections
Right arrow Coagulation
Right arrow Acute coronary syndromes

Submitted on February 18, 2003
Revised on September 11, 2003
Accepted on September 12, 2003

Involvement of Tissue Factor Pathway Inhibitor in the Coronary Circulation of Patients With Acute Coronary Syndromes

Paolo Golino MD, PhD*, Amelia Ravera MD, Massimo Ragni MD, PhD, Plinio Cirillo MD, PhD, Orlando Piro MD, and Massimo Chiariello MD

From the Department of Internal Medicine and Cardiovascular Sciences, Division of Cardiology, University of Naples Federico II, Naples, Italy. Dr Golino is currently at the Division of Cardiology, Second University of Naples, Italy.

* To whom correspondence should be addressed. E-mail: paolo.golino{at}unina2.it.

Background--Tissue factor pathway inhibitor (TFPI) is the endogenous inhibitor of the extrinsic coagulation pathway; however, its involvement during thrombus formation in patients with acute coronary syndromes (ACS) is still unknown.

Methods and Results--Transcardiac (aorta/coronary sinus) free and total TFPI (free + lipoprotein-bound form) levels, as well as TFPI/factor Xa (FXa) complex levels, were measured in plasma samples obtained from patients with acute myocardial infarction undergoing primary PTCA and patients with unstable angina undergoing urgent PTCA. Patients with stable angina undergoing elective PTCA served as controls. In addition, prothrombin fragment 1+2 and fibrinopeptide A plasma levels were measured. Samples were collected at baseline, after PTCA, and after stent deployment. In patients with ACS, both total and free TFPI plasma levels in the coronary sinus were significantly lower than the corresponding levels measured in the aorta at any time point of the study; conversely, a significant increase in TFPI/FXa complex plasma levels was observed in the coronary sinus as compared with the aorta. In contrast, in patients with stable angina, no differences were observed in TFPI and TFPI/FXa levels at baseline in the coronary sinus as compared with the aorta.

Conclusions--TFPI is involved in the process of thrombus formation in vivo in patients with ACS, which suggests a potential role for TFPI in modulating coronary thrombosis.


Key words: inhibitors, tissue factor pathway • tissue factor • acute coronary syndromes




This article has been cited by other articles:


Home page
BloodHome page
A. Undas, K. Szuldrzynski, K. E. Brummel-Ziedins, W. Tracz, K. Zmudka, and K. G. Mann
Systemic blood coagulation activation in acute coronary syndromes
Blood, February 26, 2009; 113(9): 2070 - 2078.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
R. Jaumdally, C. Varma, R. J. Macfadyen, and G. Y.H. Lip
Coronary sinus blood sampling: an insight into local cardiac pathophysiology and treatment?
Eur. Heart J., April 2, 2007; 28(8): 929 - 940.
[Abstract] [Full Text] [PDF]